.drjohnm interviews AndrewFoy82 about his meta-analysis of major cardiovascular trials looking at patients with higher comorbidity burden to see if they experience treatment benefits. ACC23 WCCardio CardioTwitter
We had patient-level data from these studies, which we got from the NHLBI BioLINCC data repository. With the individual patient-level data from the trials, we classified patients on the basis of their Charlson Comorbidity Index scores. Then we essentially redid the original analysis through the CCI-based subgroups and looked for evidence of treatment effect heterogeneity.
I think the main takeaway from the analysis of all these studies is that, generally speaking, the patient populations of the trials tended to be fairly narrow in terms of comorbidity burden, which many people might expect. One way we characterized that was by looking at the variance of the CCI scores around the median score of trial participants. It generally varied from about 1.5 to 3.25, but in general, most of the trials had a narrow population of patients. The majority of patients had comorbidity scores ≤ 4, which is about a 60-year-old patient with perhaps one or two major comorbidities.
The last finding was that, despite the narrow range of comorbidity burden within the trials, we still found treatment effect heterogeneity based on comorbidity score. It was suggested in about five trials where we foundThere was also some other treatment effect heterogeneity on a risk difference scale. Overall, we probably found about eight of what we think are potentially important interactions.
It's really hard to, from a holistic standpoint, apply that to patients who are more complex than having one variable or not. Using a comorbidity score, I think, allows us to more holistically capture patient complexity. You could make a case that it's better for finding treatment effect heterogeneity than the way that we classically do it.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Editorial: Bureaucracy of death may snag condemned Oklahoma man, guilty or notThere's no better example of the death penalty's randomness than the case of Richard Glossip in Oklahoma, who even the district attorney says was denied a fair trial. But he's still slated for a May 18 execution.
Baca lebih lajut »
The splashy corruption trial insiders fear may not yield a dropA federal corruption trial involving one of the nation’s biggest electric utilities and one of Illinois’ most well-known political figures feels like it should end with consequences — even in a city famous for elected officials behaving badly
Baca lebih lajut »
Nigeria may allow asset-backed tokens but not crypto: BloombergRegulators in Nigeria are considering licensing digital exchanges and tokens backed by assets such as equity, debt and property — but has no plans to permit crypto trading.
Baca lebih lajut »
Tech-Driven Education: Analyzing the Pivotal Trends Transforming K-12 Learning | HackerNoonMajor trends in education, impacting K-12 learning: technology, personalization, innovation, online learning, STEM, and social-emotional learning - edtech startup
Baca lebih lajut »
Warriors need Jordan Poole to flush ‘frustrating night’ and prepare for pivotal Game 7The Warriors need more from everyone in Game 7, but especially Jordan Poole.
Baca lebih lajut »
Before Harry Belafonte the star, there was an ordinary New Yorker and a pivotal encounterBelafonte, who died Tuesday at 96, spoke at length to WNYC listeners over the years, about his successes as an artist, the indignities he faced both as a Black entertainer and ordinary citizen, and the passions that drove his civil rights activism.
Baca lebih lajut »